HIV Clinical Latency: Asymptomatic Duration, Progression, and Modern Outcomes
Untreated HIV infection progresses through three stages, with a prolonged clinical latency (chronic) phase lasting median 8–10 years (range 2–15+ years).
Natural History (Untreated)
- Acute retroviral syndrome (2–4 wks post-exposure): Flu-like illness (fever, pharyngitis, lymphadenopathy, rash); high viremia; highly infectious.
- Clinical latency: Immune control partially contains virus; CD4+ T-cells decline ~50–80 cells/μL/yr. Asymptomatic or mild persistent generalized lymphadenopathy.
- AIDS (CD4 <200 or OI): Opportunistic infections, malignancies, wasting.
Progression Modifiers
- Host: HLA-B*57, CCR5-Δ32 → slower; immune activation → faster.
- Viral: Subtype, replicative capacity, set-point viral load.
- Behavioral: Smoking, alcohol, coinfections (HCV, TB), stress.
- Treatment: ART initiation at any CD4 count → viral suppression → near-normal life expectancy.
Modern Outcomes (On ART)
- Life expectancy: 20-yr-old starting ART with CD4 >500 → **near-general-population** (loss ~5–10 years, mostly from comorbidities).
- U=U (Undetectable = Untransmittable): Sustained viral suppression (<200 copies/mL) = zero sexual transmission risk.
- Comorbidity focus: CVD, renal, bone, liver, neurocognitive, cancer screening.
Key Messages
- "Asymptomatic" ≠ "no damage" – immune activation and reservoir persist.
- Test early, treat immediately. WHO: "Treat All" regardless of CD4.
- PrEP (pre-exposure prophylaxis) for high-risk negatives.
- Stigma remains barrier; normalize testing and treatment.
HIV & AIDS - Related Articles
- Ritonavir for HIV: Stages of Use and How It Works
- Navigating HIV in the Workplace: A Comprehensive Policy Guide
- Understanding HIV and AIDS: Myths and Facts
- HIV/AIDS Treatment: Antiretroviral Therapy (ART), Viral Suppression, and Long-Term Outlook
- HIV/AIDS in Africa: Key Facts & Statistics
- Understanding and Treating AIDS-Related Neuropathy
- HIV Transmission in the Workplace: Negligible Risk from Casual Contact
